Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets
Regeneron Pharmaceuticals Deferred Tax Assets and Other Non-Current Assets increased by 16.9% to $2.13B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.9%, from $1.39B to $2.13B. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 61.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase generally reflects a growing long-term asset base or deferred tax position, while a decrease suggests asset liquidation or tax benefit utilization.
Detailed definition
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets not classifi...
Peer comparison
Commonly found in the non-current asset section of balance sheets for large, diversified financial firms.
Metric ID:
deferred_tax_assets_other_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $142.90M | $145.90M | $216.10M | $262.00M | $269.90M | $320.20M | $336.40M | $349.60M | $393.20M | $409.90M | $444.10M | $470.20M | $993.80M | $1.04B | $1.14B | $1.39B | $1.54B | $1.67B | $1.82B | $2.13B |
| QoQ Change | — | +2.1% | +48.1% | +21.2% | +3.0% | +18.6% | +5.1% | +3.9% | +12.5% | +4.2% | +8.3% | +5.9% | +111.4% | +5.0% | +8.9% | +22.6% | +10.3% | +8.9% | +8.9% | +16.9% |
| YoY Change | — | — | — | — | +88.9% | +119.5% | +55.7% | +33.4% | +45.7% | +28.0% | +32.0% | +34.5% | +152.7% | +154.5% | +155.8% | +196.3% | +54.6% | +60.4% | +60.3% | +52.9% |
Range$142.90M – $2.13B
CAGR+76.6%
Avg YoY Growth+82.8%
Median YoY Growth+58.0%
Current Streak19+ quarters growth
Deferred Tax Assets and Other Non-Current Assets at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's deferred tax assets and other non-current assets?
- Regeneron Pharmaceuticals (REGN) reported deferred tax assets and other non-current assets of $2.13B in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Regeneron Pharmaceuticals's deferred tax assets and other non-current assets increased by 52.9% year-over-year, from $1.39B to $2.13B.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 61.0% compound annual growth rate (CAGR), from $168.10M to $1.82B.
- What does deferred tax assets and other non-current assets mean?
- The total value of long-term tax assets and other miscellaneous long-term assets.